Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424207 | 0.82 | EIF4A3 (0.37) | GSK3BEIF4A3CLK1SQORKDM4E | |
| SCHEMBL1750171 | 0.77 | GSK3B (0.41) | GSK3BEIF4A3HDAC6MAPK13MAPK12 | |
| SCHEMBL3424712 | 0.76 | PKN1 (0.51) | MAPK14KDM4EMEN1MAPTRAB9A | |
| SCHEMBL3422569 | 0.74 | CLK1 (0.38) | GSK3BCLK1SQORKDM4EMEN1 | |
| Trifluoroacetic Acid SCHEMBL1749441 | 0.73 | SLC22A12 (0.48) | SQORKDM4EMEN1MAPTRAB9A | |
| SCHEMBL3426237 | 0.70 | RAB9A (0.48) | GSK3BKDM4EMEN1MAPTRAB9A | |
| SCHEMBL3428892 | 0.69 | CHEK1 (0.44) | — | |
| SCHEMBL3428216 | 0.67 | F2 (0.42) | — | |
| SCHEMBL1750916 | 0.67 | GSK3A (0.54) | GSK3BKDM4EMEN1MAPTRAB9A | |
| SCHEMBL1751045 | 0.67 | KDM4E (0.47) | GSK3BKDM4EMEN1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-7968546-B2 | Pyridazinone kinase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2009-05-21 | — | — | US | disclosed |
| US-7507734-B2 | Pyridazinone derivatives | AVENTIS PHARMA S.A. (FR) | 2009-03-24 | — | — | US | disclosed |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
| EP-1604988-A1 | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2005-12-14 | — | — | EP | disclosed |
| EP-1598348-A1 | Novel pyridazinone derivatives as inhibitors of CDK2 | Aventis Pharma Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | GSK3B 1/4885EIF4A3 1416/4885HDAC6 1339/4885 |
| US-20090130209-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | GSK3B 572/4885EIF4A3 1328/4885HDAC6 1562/4885 |
| US-20070259870-A1 | Novel Pyridazinone Derivatives | CDK2, CDK1, CDK20 | GSK3B 572/4885EIF4A3 1328/4885HDAC6 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.